Can sacubitril‑valsartan (Entresto) cause cholestasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Sacubitril-Valsartan Cause Cholestasis?

Sacubitril-valsartan can cause cholestatic liver injury, though this is extremely rare, and clinicians should monitor liver function during treatment, particularly in the first few months of therapy.

Evidence for Hepatotoxicity

The FDA drug label for Entresto (sacubitril-valsartan) does not specifically list cholestasis as a known adverse effect 1. However, a published case report from 2023 documented the first case of severe liver injury caused by sacubitril-valsartan in a 90-year-old female patient who developed serious hepatic transaminase elevations after starting the medication 2. The liver injury resolved completely after drug withdrawal, establishing a clear temporal relationship and causality.

Clinical Context and Mechanism

While sacubitril-valsartan-induced cholestasis appears to be exceptionally rare, any drug can theoretically cause drug-induced cholestatic liver injury (DILI) through idiosyncratic or hypersensitive mechanisms 3. The EASL guidelines note that several hundred drugs have been reported to trigger cholestatic injury, with prevalence typically between 1 in 10,000 and 1 in 100,000 patients, though this is likely underreported 3.

Drug-induced cholestasis is defined by:

  • Isolated alkaline phosphatase >2× ULN, OR
  • ALT/AP ratio (both elevated above ULN) <2 3

Paradoxical Hepatoprotective Effects

Interestingly, the PARADIGM-HF trial demonstrated that sacubitril-valsartan actually improved conventional measures of liver function compared to enalapril, with significant reductions in total bilirubin (2.4%), AST (7.9%), ALT (7.7%), and alkaline phosphatase (5.4%) 4. This suggests that in most patients, the drug may have beneficial effects on hepatic congestion related to heart failure.

Clinical Recommendations

If cholestatic liver injury is suspected:

  1. Obtain a careful drug history and establish temporal relationship between sacubitril-valsartan initiation and liver test abnormalities 3

  2. Exclude other causes of cholestasis through appropriate workup (viral hepatitis, autoimmune disease, biliary obstruction via ultrasound) 3

  3. Immediately discontinue sacubitril-valsartan - this is the only effective treatment for drug-induced cholestasis 3

  4. Monitor liver tests closely - normalization should occur within 3 months in most cases 3

  5. Liver biopsy is not mandatory unless the course is severe, progressive, or prolonged 3

Important Caveats

  • Do not rechallenge - this is potentially harmful and unethical 3
  • Drug-induced cholestatic injury generally has a better prognosis than hepatocellular injury 3
  • The case report used supportive care (magnesium isoglycyrrhizinate and polyene phosphatidylcholine) though evidence for these interventions is limited 2
  • UDCA may be considered but is regarded as experimental due to lack of controlled trials 3

Bottom line: While sacubitril-valsartan-induced cholestasis is exceedingly rare, maintain clinical vigilance for hepatotoxicity, particularly during the initial months of therapy. The risk-benefit ratio remains highly favorable given the drug's proven mortality and morbidity benefits in heart failure 4, 5.

Related Questions

Can Valsartan (Angiotensin II Receptor Blocker) cause acute liver injury?
How should I manage a patient taking torsemide and Entresto (sacubitril/valsartan) who has a serum potassium of 3.4 mmol/L?
Can nifedipine and Entresto (sacubitril/valsartan) cause skin reactions or allergies?
In a patient with hypokalemia (serum potassium 3.2 mmol/L) on torsemide 20 mg and sacubitril/valsartan 49/51 mg, can potassium chloride be prescribed as an extended‑release 20 mEq tablet twice daily?
An elderly female patient needs antihypertensive therapy; she stopped valsartan (angiotensin receptor blocker) due to hyperkalaemia and cannot tolerate amlodipine (calcium‑channel blocker) because of leg swelling. What medication can be added to control her blood pressure?
How should a toddler with conjunctival injection (inflamed blood vessel) in the eye be evaluated and managed?
Can an elderly patient safely use a transdermal scopolamine (scopolamine) patch, and what are the appropriate dose, contraindications, and monitoring recommendations?
What is the appropriate step‑down antimicrobial regimen for an 80‑year‑old woman with an incidental urinary tract infection who is currently receiving intravenous ceftriaxone?
In a heart failure patient who develops cholestasis while on sacubitril‑valsartan (Entresto), what steps should be taken regarding the drug and what alternative heart‑failure regimen is recommended?
How should serum procalcitonin be interpreted to guide antibiotic initiation, continuation, or discontinuation in patients with suspected or confirmed pneumonia?
How should Florastor (Saccharomyces boulardii) be dosed during and after a long‑term course of Augmentin (amoxicillin‑clavulanate)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.